ELIOS 2 Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Stable or Slowly Progressing Disease.

Assess the safety and tumor response of utilizing an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine given in combination with standard of care (SoC) checkpoint inhibitors (CPI) in patients with stage IV melanoma with stable or slowly progressing disease.
Key Inclusion Criteria:

•ECOG 0 – 1
•On SOC CPI monotherapy
•Stage IV stable or slowly progressive disease
•Approximately 1 cm3 accessible and dispensable tumor
Phase IIb
Melanoma, Cutaneous (skin)
Perry Soriano
Cancer Insight, LLC
  • Providence Regional Cancer Partnership - Everett